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Abstract
Apoptosis of thymic cells induced by glucocorticoids (GC) and T-cell receptor (TCR) engagement are mutually
antagonistic. We demonstrate that cAMP enhances GC and antagonizes TCR (anti-CD3) apoptosis on the same cell (DO-
11.10 and 2B4.11 T-cell hybridomas). We analyzed the activity of several transcription factors in this cAMP dual, stimulus-
dependent, regulatory action. Anti-CD3 increases kB-activity which is inhibited by CPTcAMP or dexamethasone (DEX),
supporting the proapoptotic role of NFkB on TCR-induced apoptosis. Anti-CD3 not only increases kB- but diminishes GC
response element (GRE)-activity induced by DEX, suggesting that TCR-mediated blockade of GC-induced apoptosis
involves not only the proposed antiapoptotic action of NF-kB on GC, but also the inhibition of GRE-regulated proapoptotic
genes. To test the involvement of CRE-driven transcription in the cAMP dual apoptotic regulation, cells were transfected
with a CRE decoy DNA oligomer. Blockade of CRE transactivation with decoy targeting of CRE completely blocked the
protection of TCR-induced apoptosis by cAMP, while it did not modify the enhancement by cAMP on GC-induced
apoptosis. We show that CRE-binding factors have a definite role in T-cell apoptosis: they are involved in cAMP protection
of TCR- but not in cAMP potentiation of GC-induced apoptosis. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis in T lymphocytes occurs in a variety of
processes, e.g in deletion of autoreactive T cells dur-
ing thymic maturation [1,2], in cells attacked by cy-
totoxic T lymphocytes [3], in activation-induced cell
death and when using antibodies speci¢c for the T-
cell receptor (TCR) antigen complex [4]. A well
studied model of apoptosis is the glucocorticoid
(GC)-induced programmed cell death in immature
thymocytes [5^7], which has also been shown to oc-
cur in vivo in rats [7] and chickens [8].
Apoptosis plays a role in the deletion of peripheral
T cells and selection process of thymocytes during
their development in the thymus, and can be induced
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either by cellular activation or by exposure to GC
[9,10]. The default pathway for thymocytes bearing
TCRs with subthreshold avidity for self antigens is
death (death by neglect), which is mostly induced by
GC. Both the activation and GC-mediated apoptosis
seem to be responsible for thymocyte selection.
Based on T-cell hybridoma models it has been pro-
posed that the mutual antagonism among activation-
induced and steroid-mediated pathways play a crit-
ical role in the selection process [5,8^11]. In the pe-
riphery, TCR signaling initiates the cellular immune
response activating T cells. In turn, TCR stimulation
of already activated mature T cells can undergo ap-
optosis. This process is denominated activation-in-
duced cell death. This is also inhibited by GC, indi-
cating that GC also mediate survival or apoptosis in
mature T cells [12]. Understanding the molecular ba-
sis for T-cell apoptosis has been greatly aided by the
development of cell culture systems, such as T-cell
hybridomas, amenable to genetic manipulations.
The involvement of cAMP in programmed cell
death has been studied in di¡erent systems, and is
far from clear in T cells yet. Some controversial re-
sults have been reported. It induces apoptosis in a rat
myeloid leukemic cell line [13]. In mouse fetal thymus
organ cultures the cAMP signaling pathway blocks
di¡erentiation of thymocytes at an early maturation
stage [14]. In primary cultures of mice thymocytes
cAMP was also shown to potentiate GC-induced ap-
optosis [15]. In B10 T-cell hybridomas, cAMP-elevat-
ing agents have been shown to prevent TCR-induced
apoptosis with minimal inhibition of interleukin-2
production [16] and antagonism of Fas-dependent
activation [17]. cAMP analogs induced DNA frag-
mentation in 9C12.7 but not in other T-cell hybrid-
omas and did not in£uence GC-induced apoptosis in
all these cell lines [18].
cAMP transcriptional activity is essentially medi-
ated by CREB (cAMP-responsive element binding
protein), a 43 kDa basic/leucine zipper transcription
factor that binds to the octanucleotide CRE element
(TGANNTCA) both as homodimer and as hetero-
dimer in conjunction with other members of the
CREB/ATF superfamily of transcription factors
such as cAMP-responsive element modulator
(CREM) [19]. The mammalian NF-kB transcription
factors, which include p50/p105, p52/p100, RelA
(p65), c-Rel and RelB, play important roles in the
regulation of immune responses, cellular prolifera-
tion and cell death (reviewed in [20]). Transcriptional
activation or repression of NF-kB target genes re-
quires the binding of NF-kB dimers to kB DNA-
binding sites. In most cells, the transcriptional activ-
ity of NF-kB proteins is controlled at the posttrans-
lational level by association with members of a fam-
ily of inhibitory proteins (IkBs). The glucocorticoid
receptor (GR) acts on target cells primarily through
transcriptional activity through binding of the GR to
the DNA glucocorticoid responding elements (GRE)
[21]. The cross-talk between transcription factors
modulates the responsiveness of cells to di¡erent
stimuli. Cross-talk of GR with AP-1 and NF-kB
has been shown to be the molecular substrate of
GC inhibition of cytokine expression and action
[22^26]. A complex cAMP-dependent GR regulation,
involving changes in receptor transcript level, ligand
binding and phosphorylation status has been de-
scribed [27^29]. For these transcription factors, e.g.,
CREB, NF-kB and GR, both pro- and antiapoptotic
actions have been described in di¡erent cell types
[11,30^33].
The putative integrative regulation of cAMP-medi-
ated pathways in the GC/TCR-induced apoptosis has
not yet been studied. In the present report we ad-
dress this question as well as the involvement of
the main transcription factors implicated in these
pathways making use of the T-cell hybridoma mod-
els utilized to de¢ne the mutual antagonism among
activation-induced and steroid-mediated pathways.
2. Materials and methods
2.1. Materials
Unless stated, reagents used in the present work
were obtained from Sigma Chemical Co. (St. Louis,
MO).
2.2. Cell culture and stimulation
Cell culture procedures have been previously de-
scribed [26,34]. DO-11.10 mouse T-cell hybridoma
(generously provided by Dr. Makoto Iwata, Mitsu-
bishi Kasei Institute of Life Sciences, Tokyo, Japan)
was grown in Dulbecco’s modi¢ed Eagle’s medium
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(DMEM) (Gibco Laboratories, Grand Island, NY,
USA) supplemented with 10% heat-inactivated FCS
(Gibco, Paisley, UK), penicillin (100 units/ml), strep-
tomycin (100 Wg/ml), 3 mM L-glutamine, 50 WM L-
mercaptoethanol and 100 mM non-essential amino
acids (Gibco, Paisley, UK). 2B4.11 mouse T-cell hy-
bridoma (generously provided by Dr. Jonathan Ash-
well, NIH, USA) was grown in RPMI 1640 (Gibco
Laboratories) supplemented with 10% heat-inacti-
vated FCS, 4 mM L-glutamine, 50 WM L-mercapto-
ethanol, penicillin (100 units/ml) and streptomycin
(100 Wg/ml). The cells were maintained at 37‡C in a
humidi¢ed atmosphere of 5% CO2. The same me-
dium as for cell maintenance was used for cell
growth and plating before the experiments took
place.
DO-11.10 and 2B4.11 cells (105 cells/ml) were ac-
tivated with plate-bound 145.2C11 anti-CD3 anti-
bodies (Pharmingen, USA), coated overnight at
4‡C in Tris^HCl 40 mM bu¡er (pH 9.5). The follow-
ing substances were also used: dexamethasone
(DEX), a synthetic GC; CPTcAMP, dibutyryl-
cAMP and 8-Br-cAMP, cell-permeable analogs of
cAMP; forskolin, an adenylyl cyclase activator and
isoproterenol, a L-adrenergic agonist (Research Bio-
chemicals International, Natick, MA). After treat-
ments, cells were harvested and analyzed to assess
cell death (acridine orange staining, FACS and
DNA fragmentation), and luciferase (LUC) activity.
In some experiments, transfection of reporter plas-
mids or dsDNA oligonucleotides was performed pri-
or to treatment.
2.3. Acridine orange/ethidium bromide staining
Mortality was evaluated adding £uorescent dyes
that bind to DNA and subsequently examining the
cells under an ultraviolet light microscope (Leica,
Germany). At di¡erent times post-treatment (as in-
dicated), 100 Wl of cell suspension and 100 Wl of a 1:1
PBS solution of acridine orange 1 mg/l and ethidium
bromide 20 mg/l were mixed and immediately ob-
served under ultraviolet light. Ethidium bromide
only enters into non-viable/death cells and stains
chromatin a dark orange color. Acridine orange pen-
etrates in viable cells and turns green when it inter-
calates with DNA. At least 200 cells per condition
were counted.
2.4. Flow cytometry
Apoptosis was also evaluated by double staining
with propidium iodide and annexin V-FITC (Bender
MedSystems, Vienna, Austria). After the di¡erent
treatments, 5U105 cells were washed once with
PBS, resuspended in binding bu¡er (10 mM
HEPES/NaOH, pH 7.4; 140 mM NaCl; 2.5 mM
CaCl2) and incubated on ice in darkness for 30 min
with 2 Wl of annexin V-FITC 20 mg/ml and 2 Wl of
propidium iodide (1 mg/ml stock). Samples were
washed three times with 2 ml of binding bu¡er and
then analyzed by £ow cytometry in a Cytoron Abso-
lute (Ortho Diagnostic Systems, New Brunswick, NJ,
USA) cytometer equipped with a 488 nm argon laser.
Data were obtained with ImmunoCount (Ortho Di-
agnostic Systems) software.
2.5. DNA laddering apoptosis assay
Each cell suspension (5U106 cells) was washed
twice with PBS and the cell pellet was resuspended
in 800 Wl of lysis bu¡er (0.2% Triton X-100; 10 mM
Tris^HCl, pH 7.5; 10 mM EDTA) [26]. After 10 min
on ice, the lysate was centrifuged (14 000 rpm) for 10
min at 4‡C and a phenol-chloroform/isoamyl alcohol
(24:1) extraction of the supernatant was performed.
The aqueous phase was precipitated with sodium
acetate 30 mM and 0.7 volumes of isopropanol.
The pellet was washed with 80% ethanol, dried and
resuspended in 100 Wl TE (10 mM Tris^HCl, 1 mM
EDTA, pH 8). Samples were treated with RNAse A
(0.5 mg/ml) for 1 h. at 37‡C, then a phenol-chloro-
form/isoamyl alcohol extraction was performed and
the aqueous phase was precipitated with 2 volumes
of ethanol. The nucleic acid pellet was resuspended
in 40 Wl of bu¡er TE, and electrophoresis was carried
out in a 2% agarose gel in TBE bu¡er; DNA was
visualized by ethidium bromide staining. A 123 bp
marker (Gibco BRL, Grand Island, NY, USA) was
used in parallel as an indicator of molecular mass.
2.6. Plasmids, transfections, and assay of luciferase
activity
Reporter plasmids for GRE (MTV-LUC provided
by Dr. R. Evans, Howard Hughes Medical Institute,
La Jolla, CA, USA), CRE (vMTV-5CRE-LUC pro-
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vided by Dr. Dietmar Spengler, Max Planck Institute
of Psychiatry, Munich, Germany) and kB sites (kB-
LUC provided by Dr. M. Bell, Mayo Clinic, Roches-
ter, MN, USA) have been described elsewhere [35^
38].
DO.11-10 and 2B4.11 cells were transfected by
electroporation, according to a described method
[26,39], with small modi¢cations. Brie£y, cells cul-
tured in maintenance medium were washed with
PBS and the cellular pellet was resuspended in elec-
troporation medium (DMEM with 3 mM L-gluta-
mine and 50 WM L-mercaptoethanol). Cells (107 in
0.2 ml) were transferred to a 4-mm-gap electropora-
tion cuvette (Bio-Rad Laboratories, Richmond, CA,
USA) and 20 Wg of the indicated reporter plasmid
was added, followed by a 10-min incubation at room
temperature. Transfection was carried out using an
electroporation system Gene Pulser II (Bio-Rad Lab-
oratories) at 250 V, 975 mF. Electroporated cells
were replated in maintenance medium and incubated
immediately with the di¡erent agents. After 6 or 24 h,
cells were harvested and extracts were assayed for
LUC activity [26] using a Promega (Madison, WI,
USA) kit. Brie£y, 20 Wl of the extract were incubated
with 100 Wl of the Luciferase Assay Bu¡er in partial
darkness and immediately assessed for luciferase ac-
tivity in a Junior luminometer (Berthold, Germany).
In order to correct for variations in the total number
of harvested cells during extract preparation, relative
luminescence units (RLU) were normalized with re-
spect to the total protein content of each extract,
according to the Bradford method [40].
2.7. Decoy targeting
DO.11-10 cells were transfected with dsDNA oli-
gonucleotides using the same protocol as for plasmid
transfection, with minor modi¢cations. These oligo-
nucleotides are speci¢cally designed to bind to par-
ticular transcription factors and are used to dampen
the content of these factors within the cell [41]. Due
to the transfection procedure, which involves di¡er-
ent cell batches for each DNA transfected and in-
creased basal mortality levels, some di¡erences in
basal cell death number are observed in decoy target-
ing experiments. The indicated amount of oligonu-
cleotides were transfected and cells were incubated
for 1 h at 37‡C, 5% CO2 before exposing them to the
di¡erent treatments. An oligomer with the CRE
site (sequence: 5P-AGCTTAGGGCTCGTTGACGT-
CACCAAG-3P) or a control oligonucleotide (5P-AG-
CTTAGGGCTCGTTGACGTCTCCAAG-3P) were
used. This latter has the same base composition but
an inverted base pair, which renders it unable to bind
CREB proteins [38]. In preliminary experiments we
proved the ability of the CRE oligonucleotide to
block CRE transcriptional activity, in contrast to
the control oligonucleotide. For convenience we
will use the term CREB to refer to the CREB super-
family of transcription factors (which bind to CRE).
2.8. Statistics
Statistics were performed using one-way analysis
of variance (ANOVA) in combination with Sche¡e¤’s
test. Results are expressed as mean þ S.E.M.
3. Results
3.1. cAMP has an opposite action on GC and
TCR-induced apoptosis in the same cell
In order to assess the role of cAMP as a modula-
tor of GC and TCR-mediated programmed cell
death, two types of mouse T-cell hybridomas were
used: DO-11.10 and 2B4.11. Unless speci¢ed, the
results were identical in these two cell lines. As
shown for DO-11.10 cells, anti-CD3 (which mimics
TCR engagement) or DEX treatment induced apo-
ptosis, as evaluated by acridine orange staining after
16 h (Fig. 1A). The cAMP analog CPTcAMP poten-
tiated the e¡ect of DEX, but signi¢cantly decreased
anti-CD3 triggered apoptosis (Fig. 1A); similar re-
sults were obtained with forskolin (an adenylyl cy-
clase activator) and isoproterenol (a L-adrenergic ag-
onist) (not shown). CPTcAMP had no e¡ect by itself
on apoptosis, and the mutual inhibition of TCR- and
GC-mediated apoptosis was also evident (Fig. 1A).
At these doses, DEX and CPTcAMP elicited a quan-
titatively similar protection. Both regulatory e¡ects
of cAMP were also con¢rmed by £ow cytometry
with annexin V-FITC staining (an early marker of
apoptosis) (Fig. 1B) and by agarose gel electropho-
resis (to determine the DNA laddering pattern ob-
served after internucleosomal cleavage) (not shown).
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In these experiments we demonstrate, for the ¢rst
time, that cAMP exerts a dual regulatory action on
the same cell, depending on which is the stimulatory
pathway for apoptosis.
3.2. GRE and kB activity during T-cell hybridoma
apoptosis triggered by GC, TCR and cAMP
Since cAMP-modulated factors could be playing a
role in a cross-talk with signals that trigger other
important transcriptional regulators (such as acti-
vated GR and NF-kB), DO-11.10 cells were trans-
fected with reporter plasmids to assess transcription-
al activity levels of factors that bind to GRE and kB-
sites. MTV-LUC (a LUC construct containing four
tandem repeats of GRE) [35] was used to evaluate
modulation of GR transcriptional activity. DEX
treatment of T-cell hybridoma strongly increased
LUC expression mediated by GREs, while anti-
CD3 stimulation inhibited DEX-mediated GRE-
transactivation. CPTcAMP did not modify GRE-
driven activity (Fig. 2). To study NF-kB transcrip-
tional activity, we used a kB-LUC plasmid contain-
ing 3 kB sites from the HIV enhancer coupled to
luciferase [36]. kB activity levels were induced by
anti-CD3 stimulation and inhibited by treatment
with either DEX or CPTcAMP (Fig. 3), while both
together had not further additive e¡ects (not shown).
Similar e¡ects were observed when cells were stimu-
lated only with DEX, CPTcAMP or a combination
of the two.
3.3. CRE-driven transcription exerts an anti-apoptotic
regulation. Role of CRE-binding factors as
inhibitors of TCR-induced apoptosis
To further analyze the dual e¡ect of cAMP signal
transduction pathways on GC- and TCR-induced
apoptosis, we transfected DO-11.10 cells with a
Fig. 1. cAMP di¡erentially modulates GC- and TCR-induced
apoptosis on the same cell. (A) DO.11-10 cells were incubated
with optimal doses of DEX (1 WM), CPTcAMP (500 WM) and
anti-CD3 (500 ng/ml), as indicated. Cell mortality percentage
was assessed 16 h after treatment with acridine orange plus
ethidium bromide staining and £uorescence microscopy, as de-
scribed in Section 2. The error bars correspond to the mean of
quadruplicate samples þ S.E.M. Similar results were obtained in
three independent experiments. *P6 0.001 with respect to basal
condition; **P6 0.001 with respect to DEX on its own;
***P6 0.001 with respect to anti-CD3 on its own (ANOVA
with Sche¡e¤’s test). (B) DO.11-10 T-cell hybridoma cells were
stimulated for 16 h as in A. Subsequently, cells were analyzed
by £ow cytometry to assess annexin V-FITC binding. Simulta-
neously, cells were incubated with propidium iodide to evaluate
cell viability (not shown). Representative £uorescence histo-
grams from one of two separate experiments with triplicates are
shown.
Fig. 2. Anti-CD3 treatment inhibits DEX-mediated increase of
GRE-mediated transcription. 107 DO-11.10 cells were trans-
fected with 20 Wg of GRE-LUC and stimulated with 100 nM
DEX, 500 WM CPTcAMP and 500 ng/ml anti-CD3. After 24 h
incubation, cells were harvested for extract preparation and
LUC activity determination; fold activity with respect to basal
levels is shown. LUC activity is the mean of three normalized
measurements þ S.E.M. Similar results were obtained in four in-
dependent experiments.
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CRE-LUC reporter plasmid (vMTV-5CRE-LUC),
which has deleted the GRE-containing sequences
but possesses ¢ve CRE tandem repeats [37,38] (Fig.
4). As expected, all treatments with CPTcAMP en-
hanced CRE-driven transcription, either with or
without DEX or anti-CD3 stimulation.
Anti-CD3 stimulation decreased basal levels of
CRE activity by 70%. Both co-treatment with DEX
or the cAMP analog blocked this inhibition, up to
basal (in the case of DEX) or even higher levels (Fig.
4). CPTcAMP induction of CRE activity was weaker
when presented in combination with anti-CD3. DEX
partially inhibited the e¡ect of the cAMP analog
when presented without anti-CD3 stimulation. These
results show that anti-CD3 treatment decreases basal
levels of CRE-driven activity, while inhibitors of
TCR-mediated cell death reverse these e¡ects.
These results suggested a putative protective e¡ect
for CRE-binding factors in TCR-induced apoptosis.
To test this hypothesis, we transfected DO-11.10 cells
with dsDNA oligonucleotides carrying the CRE con-
sensus sequence (an approach termed ‘decoy target-
ing’), and evaluated cell death after the di¡erent
treatments. Blockade of CRE-driven transcriptional
activity completely blocked cAMP protection of
TCR-induced apoptosis, while an identically com-
posed scrambled control oligonucleotide had no ef-
fect (Fig. 5A). We also analyzed if CRE-binding fac-
tors participated in CPTcAMP potentiation of GC-
induced cell death. As shown in Fig. 5B, the same
CRE oligonucleotide did not change the enhance-
ment exerted by the cAMP analog on DEX-mediated
apoptosis; the fold increase of mortality was identi-
cal in control and CRE oligonucleotides (comparing
DEX versus DEX+CPTcAMP treatments). Other ex-
periments with di¡erent doses of oligonucleotides
had a similar, dose-dependent result (not shown).
4. Discussion
In the last 10 years, a signi¢cant amount of work
has been done to understand the regulatory mecha-
nisms underlying thymic and T-cell apoptosis, mainly
using T-cell hybridomas as cellular models [10,11,
39,42,43]. In this work we report for the ¢rst time
the dual e¡ect that cAMP exerts on apoptosis in the
same cell, using two models, DO.11-10 and 2B4.11
T-cell hybridomas, and we show that CRE-binding
factors have a de¢nite role in T-cell apoptosis: they
are involved in cAMP protection of TCR- but not in
cAMP potentiation of GC-induced apoptosis.
We also analyzed the involvement of other tran-
scription factors, performing functional reporter as-
says which give a clear insight on the transcription
status of the factors. The role of NF-kB in the reg-
Fig. 4. CRE transcriptional activity is inhibited by anti-CD3
treatment. 107 DO-11.10 cells were transfected with 20 Wg of
vMTV-5CRE-LUC plasmid and stimulated with 100 nM DEX,
500 WM CPTcAMP and 500 ng/ml anti-CD3. After 6 h incuba-
tion, cells were harvested for extract preparation and LUC ac-
tivity determination; fold activity with respect to basal levels is
shown. LUC activity is the mean of three normalized measure-
ments þ S.E.M. Similar results were obtained in four independ-
ent experiments.
Fig. 3. Enhancement of kB-driven transcriptional activity by
anti-CD3 treatment and inhibition by co-stimulation with DEX
or CPTcAMP. 107 DO-11.10 cells were transfected with 20 Wg
of kB-LUC and stimulated with 100 nM DEX, 500 WM
CPTcAMP and 500 ng/ml anti-CD3. After 6 h incubation, cells
were harvested for extract preparation and LUC activity deter-
mination; fold activity with respect to basal levels is shown.
LUC activity is the mean of three normalized measurements þ
S.E.M. Similar results were obtained in three independent ex-
periments.
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ulation of apoptosis is still under evaluation. In some
models has been shown to be proapoptotic, whereas
in others an antiapoptotic action has been demon-
strated [32,39,44,45]. For example, downregulation
of kB activity in T A1.1 hybridoma using an inhib-
itory peptide results in a signi¢cant decrease in Fas
ligand expression and apoptosis in response to TCR
ligation [46]. A recent report using T-cell hybridoma
2B4.11 as a model shows that this nuclear factor can
perform both functions in the same cell, depending
on the stimuli. In that study, blocking of NF-kB
activity was shown to inhibit TCR-mediated apopto-
sis, while potentiating GC-induced apoptosis [39]. kB
transcriptional activity has not been previously eval-
uated in these cells. Our results, which show an in-
crease in kB activity by anti-CD3, are in line with
this proapoptotic role of NF-kB by TCR-engage-
ment. This recent study performed by Scheinman’s
group lead them to propose that NF-kB protection
of GC-mediated apoptosis would represent a mech-
anism by which thymocytes survive during positive
selection [39]. In order to induce apoptosis, GC
should not only induce apoptosis-promoting genes
but also induce genes (such as IkB) that block apo-
ptosis inhibitors. The results of our transfection ex-
periments with GRE- and kB-reporter plasmids
(Figs. 2 and 3), showing that TCR engagement in-
creases kB- and diminishes GRE-driven activity in-
duced by DEX, suggest that TCR-mediated blockade
of GC-induced apoptosis probably involves not only
the previously demonstrated antiapoptotic action of
NF-kB on GC and its proapoptotic activity on TCR
ligation without GC, but also the inhibition of GRE-
regulated proapoptotic genes. In fact in knock-in
mice for the GR, it has been shown that GR trans-
activation is essential for the proapoptotic action of
GC on thymocytes [47]. In addition, we observed
that cAMP inhibited both basal and TCR-induced
kB transactivation. These results are in agreement
with previous publications. In human endothelial
cells it has been shown that cAMP inhibits NF-kB-
mediated transcription [48,49], while in T cells it has
been shown that cAMP antagonizes Fas dependent
activation induced cell death accompanied by a
downregulation of NF-kB levels shown by gel shift
[17] and that TCR-coupled Fas ligand expression
and apoptosis was inhibited by cAMP [50]. In that
paper a series of experiments in other cell lines sug-
gested that the inhibition of Fas ligand expression by
cAMP in T-cell hybridomas may be correlated with a
speci¢c inhibition of NF-kB [50]. The concomitant
inhibition by cAMP of TCR-induced cell death and
Fig. 5. Decoy targeting of CRE-binding factors with CRE oli-
gonucleotide show CREB involvement in cAMP protection of
TCR-induced apoptosis but not in cAMP potentiation of GC-
mediated programmed cell death. DO.11-10 cells were trans-
fected with 1.5 Wg of dsDNA oligonucleotides containing CRE
or control sequences (see Section 2). After 1 h incubation at
37‡C, cells were stimulated with plate-bound anti-CD3 500 ng/
ml, CPTcAMP 500 WM or DEX 100 nM, as indicated. Sixteen
hours later cell mortality percentage was assessed with acridine
orange plus ethidium bromide staining. The error bars corre-
spond to the mean of triplicate samples þ S.E.M. Similar results
were obtained in three independent experiments. Di¡erences in
basal levels are due to the use of di¡erent cell batches for each
transfected DNA. Higher basal mortality, compared to Fig. 1,
is due to the transfection procedure. (A) *P6 0.05 with respect
to control oligo/anti-CD3; **P6 0.01 with respect to control
oligo/basal condition; ***P6 0.01 with respect to CRE oligo/
basal condition; vP6 0.05 with respect to CRE oligo/basal con-
dition and similar to CRE oligo/anti-CD3 (ANOVA with
Sche¡e¤’s test). (B) *P6 0.01 with respect to control oligo/basal
condition; **P6 0.01 with respect to control oligo/DEX condi-
tion; ***P6 0.001 with respect to CRE oligo/basal condition;
vP6 0.05 with respect to control oligo/DEX condition (AN-
OVA with Sche¡e¤’s test).
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kB transcriptional activity that we describe for the
¢rst time in a T-cell model, further supports the
proapoptotic role that NF-kB may exert on TCR-
induced apoptosis.
Studies performed during the 1970s presented the
¢rst evidence that cAMP promotes apoptosis. cAMP
pharmacological agonists are also cytotoxic in lym-
phoid cell lines, and stimulate DNA fragmentation in
thymocytes [16]. More recent work has extended
these observations to other cellular models, including
immortalized primary granulosa cells, human mam-
mary carcinoma cells, and a variety of normal and
transformed T and B cells [51,52]. According to our
studies, the cAMP signaling pathway has no e¡ect
per se in T-cell hybridoma apoptosis; moreover,
cAMP e¡ects are most likely context-dependent.
This is further indicated by evidence showing that
in other models cAMP can block apoptosis. The
best known example is probably the e¡ect of
cAMP on neurons, where it inhibits apoptosis trig-
gered by ex vivo culture, nerve growth factor deple-
tion or extracellular potassium [53]. It also prevents
spontaneous apoptosis of aged neutrophils, ovary
follicles [54] and, as shown in the present report
and others, TCR-activated T cells [16,18,55]. To
this day, it is not known if the same molecular tar-
gets are responsible for the apoptosis suppressing
and promoting roles of cAMP.
CRE-binding factors are of major signi¢cance in
current molecular physiology, in particular the
CREB transcription factor. There is evidence that
within the nervous system CREB plays a key role
in the regulation of apoptosis. In addition, studies
using CREB null mice or transgenic mice expressing
a dominant negative of CREB suggest that it is nec-
essary in thymus for the proper maturation of T
lymphocytes [56,57]. In this work we demonstrate
that CREB proteins are key mediators in the protec-
tion exerted by cAMP signaling on TCR-induced ap-
optosis (Fig. 5A). The molecular targets of CREB
transcriptional regulation remain unknown; they
may include several antiapoptotic genes which are
reportedly up-regulated by cAMP through CREs in
their promoters (such as bcl-2 family members mcl-1,
bcl-xL and bcl-2 [41,58,59]) or FasL, which is also
regulated by cAMP and is critical for T-cell apopto-
sis [17,50].
The experiments shown in Fig. 5 also establish
that CRE-driven transcription is essential for
cAMP action on TCR-mediated apoptosis, but has
no apparent e¡ect on the potentiation by cAMP
of GC-dependent cell death. Interestingly, while
CPTcAMP synergizes with DEX in the induction
of apoptosis, DEX blocks CPTcAMP induction of
CRE activity. A hypothetical explanation would be
that GR interacts with a repressive CRE binding
protein to promote apoptosis. Although in this study
we focus on the cross-talk at the transcriptional level,
GR and cAMP pathways may regulate each other
upstream in the signal cascade, as for example re-
cently described for the MAPK pathway in the
GR/TCR antagonism [43]. The variations in mortal-
ity basal levels after CRE transfection may be due to
the fact that di¡erent batches of cells were used in
each electroporation (as stated in Section 2), and/or
that competition for common coactivators (e.g.,
CREB binding protein, CBP) is taking place (Fig.
5). In addition, CREB or CBP very likely may be
involved in the cAMP inhibition of NF-kB transac-
tivation following TCR stimulation discussed above.
During stress, a number of hormones and neuro-
transmitters are released, in order to modify the sys-
tem equilibrium toward a new condition where it can
deal with the novel situation. Both systemic adrena-
line and locally released noradrenaline participate in
this mechanism, acting through adrenergic receptors.
These act mainly by modulating the levels of cAMP,
hence emphasizing a putative modulatory role for
substances that transduce signals through this second
messenger. Lymphoid tissues such as spleen and thy-
mus, in particular, are abundantly innervated by ad-
renergic ¢bers. This is especially true during develop-
ment, when it is believed that they may play a role in
the di¡erentiation and survival of developing T cells
[60,61]. Furthermore, the potentiation of GC-medi-
ated apoptosis with cAMP observed in this study
and others [15] suggests a possible role of cAMP-
elevating agents in thymic involution observed dur-
ing stress.
Based on these results, further investigation will be
required to determine the targets of GC, cAMP and
TCR ligation in the development of thymocytes and
T cells in primary cultures. Also, whether this dual
modulatory stimulus-dependent role of cAMP/CRE
in cell survival takes place in other cell types requires
further study.
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